BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01498185. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Explore the Safety, Pharmacokinetics and Pharmacodynamics of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
Study identification
- NCT ID
- NCT01498185
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2012 (Type not available)
- Primary completion
- Oct 2012 (Actual)
- Completion
- Oct 2012 (Actual)
- Last update posted
- Feb 10, 2017
2012
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Profil Institute For Clinical Research, Inc. | Chula Vista | California | 91911 | — |
| Va San Diego Healthcare System | San Diego | California | 92161 | — |
| La Biomed Research Inst. At Harbor Ucla Med Ctr. | Torrance | California | 90502 | — |
| Compass Research Phase 1, Llc | Orlando | Florida | 32806 | — |
| Progressive Medical Research | Port Orange | Florida | 32127 | — |
| Vince And Associates Clinical Research | Overland Park | Kansas | 66212 | — |
| Central Kentucky Research Associates, Inc. | Lexington | Kentucky | 40509 | — |
| Louisiana Research Associates, Inc. | New Orleans | Louisiana | 70114 | — |
| Jasper Clinic, Inc. | Kalamazoo | Michigan | 49007 | — |
| Kansas City University Of Medicine And Biosciences | Kansas City | Missouri | 64106 | — |
| Regional Medical Clinic-Endocrinology | Rapid City | South Dakota | 57701 | — |
| Dallas Diabetes & Endocrine Center | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01498185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2017 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.